PYPD
Price
$4.29
Change
-$0.08 (-1.83%)
Updated
Jul 31 closing price
Capitalization
82.26M
9 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$96.55
Change
-$1.78 (-1.81%)
Updated
Aug 3, 12:12 PM (EDT)
Capitalization
8.54B
3 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

PYPD vs SYRE

PYPD vs SYRE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PYPD vs. SYRE commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PYPD is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (PYPD: $4.29 vs. SYRE: $98.33)
Brand notoriety: PYPD and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PYPD: 43% vs. SYRE: 22%
Market capitalization -- PYPD: $82.26M vs. SYRE: $8.54B
PYPD [@Biotechnology] is valued at $82.26M. SYRE’s [@Biotechnology] market capitalization is $8.54B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PYPD’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • PYPD’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SYRE is a better buy in the long-term than PYPD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PYPD’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 2 bullish TA indicator(s).

  • PYPD’s TA Score: 5 bullish, 5 bearish.
  • SYRE’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, PYPD is a better buy in the short-term than SYRE.

Price Growth

PYPD (@Biotechnology) experienced а +10.00% price change this week, while SYRE (@Biotechnology) price change was -3.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

PYPD is expected to report earnings on Aug 12, 2026.

SYRE is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($8.54B) has a higher market cap than PYPD($82.3M). SYRE YTD gains are higher at: 200.153 vs. PYPD (-1.152). PYPD has higher annual earnings (EBITDA): -33.47M vs. SYRE (-241.64M). SYRE has more cash in the bank: 741M vs. PYPD (10.9M). SYRE has less debt than PYPD: SYRE (0) vs PYPD (2.34M). PYPD (0) and SYRE (0) have equivalent revenues.
PYPDSYREPYPD / SYRE
Capitalization82.3M8.54B1%
EBITDA-33.47M-241.64M14%
Gain YTD-1.152200.153-1%
P/E RatioN/A1.72-
Revenue00-
Total Cash10.9M741M1%
Total Debt2.34M0-
FUNDAMENTALS RATINGS
PYPD vs SYRE: Fundamental Ratings
PYPD
SYRE
OUTLOOK RATING
1..100
5095
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
6034
P/E GROWTH RATING
1..100
5579
SEASONALITY SCORE
1..100
3549

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PYPD's Valuation (53) in the null industry is in the same range as SYRE (74) in the Pharmaceuticals Major industry. This means that PYPD’s stock grew similarly to SYRE’s over the last 12 months.

PYPD's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that PYPD’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as PYPD (100) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.

SYRE's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as PYPD (60) in the null industry. This means that SYRE’s stock grew similarly to PYPD’s over the last 12 months.

PYPD's P/E Growth Rating (55) in the null industry is in the same range as SYRE (79) in the Pharmaceuticals Major industry. This means that PYPD’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PYPDSYRE
RSI
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 8 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
82%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
81%
MACD
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 11 days ago
88%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PYPD
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LGPIX58.680.83
+1.43%
ProFunds Large Cap Growth Inv
DIEFX16.950.02
+0.12%
Destinations International Equity I
GCICX19.37-0.10
-0.51%
Goldman Sachs Intl Eq Insghts C
IARYX18.44-0.12
-0.65%
Invesco Real Estate Y
CRCRX11.05-0.08
-0.72%
NYLI CBRE Real Estate Class C

PYPD and

Correlation & Price change

A.I.dvisor indicates that over the last year, PYPD has been loosely correlated with LSTA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if PYPD jumps, then LSTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PYPD
1D Price
Change %
PYPD100%
-1.83%
LSTA - PYPD
35%
Loosely correlated
-3.88%
RCUS - PYPD
32%
Poorly correlated
-0.21%
AMLX - PYPD
29%
Poorly correlated
-2.12%
SYRE - PYPD
29%
Poorly correlated
-3.12%
INM - PYPD
28%
Poorly correlated
-2.00%
More